Salute e Benessere

RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER

NEWS RELEASE Milan, 23 October 2025– Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headquarters in Milan.Mike McClellan, an American national, is a seasoned CFO in the pharmaceutical industry with nearly 30 years of experience across various geographies. Most recently, he served as CFO of Almirall (2019-2025) where he played a pivotal role in...
Nasdaq GlobeNewswire
23/10/2025

Pharming Group to report third quarter 2025 financial results and provide…

Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in...
Nasdaq GlobeNewswire
23/10/2025

THERANEXUS : THX Pharma announces the launch of a capital increase with…

Subscription and guarantee commitments totaling €5.9 million, representing 75.5% of the envisaged capital increase Subscription price: €1.80 per share, representing a 29.4% discount to the closing price of the share on October 22, 2025 Subscription ratio: 6 new shares for 13 existing shares Detachment of preferential subscription rights on October…
Actusnews Wire
23/10/2025

Essity: Interim Report Quarter 3, 2025

CEO'S COMMENTS CEO'S COMMENTS Our efforts to drive growth and reduce costs have yielded results and the third quarter developed favourably in continued challenging market conditions. In parallel, we are today launching measures aimed at creating better conditions for profitable growth - an organizational change and a cost savings program. Positive organic sales growth Organic growth was positive compared with the third quarter of the previous year, mainly driven by higher prices...
PR Newswire
23/10/2025

Changes to the Roche Enlarged Corporate Executive Committee

Nina Schwab-Hautzinger rejoins Roche from her role at BASF as Head of Corporate Communications and Government Relations. During her previous thirteen year tenure at Roche, Nina Schwab-Hautzinger held various communications leadership roles such as Head of Corporate Brand & Communications at the Group level and Head of Communications & Public Affairs for Pharma in Germany. She has also led the healthcare practice in a strategic communications consultancy in Singapore.Nina...
Nasdaq GlobeNewswire
23/10/2025

Nicox Provides First Half 2025 Financial Results

Press ReleaseNicox Provides First Half 2025 Financial Results New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026October 23, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today...
Nasdaq GlobeNewswire
23/10/2025

Essity strengthens conditions for profitable growth

The organizational change will simplify Essity's structure and create end-to-end accountability. This will further enhance customer and consumer focus, increase speed, agility, and operational efficiency. The change facilitates increased strategic focus on the product categories and segments with the greatest potential for profitable growth. The organizational change will simplify Essity's structure and create end-to-end accountability. This will further enhance customer and consumer focus,...
PR Newswire
23/10/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth…

Basel, 23 October 2025 Group salesgrew by 7% 1at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals Divisionsales rose by 9% (4% in CHF) due to continued high growth in sales of medicines for the treatment of severe diseases; Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (serious eye diseases) and Ocrevus (multiple sclerosis) were the top...
Nasdaq GlobeNewswire
23/10/2025

SheMed Raises $50M to Scale Personalised Women's Health Services

The new funding will be used to expand SheMed's UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its data-driven capabilities. The investment will also support new research and patient-experience initiatives designed to improve access to high-quality, personalised care for women across the UK. The new funding will be used to expand SheMed's UK operations, scaling its medical and technology teams, strengthening clinical infrastructure...
PR Newswire
23/10/2025

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for…

Glomerulonephritis Market Summary Glomerulonephritis Market Summary Discover the glomerulonephritis new treatment @New Treatments for Glomerulonephritis Key Factors Driving the Growth of the Glomerulonephritis Market Rising Incidence of Glomerulonephritis and Associated Conditions The increasing prevalence of autoimmune diseases, diabetes, hypertension, and infections such as post-streptococcal glomerulonephritis is contributing to a higher incidence of GN cases,...
PR Newswire
22/10/2025

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5…

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the...
PR Newswire
22/10/2025

Probiotic Market to Reach USD 280.37 Billion Globally by 2032, Growing At An…

The report, titled "Probiotic Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032," provides a granular view of the forces shaping this dynamic industry. Probiotics, defined as live microorganisms that confer a health benefit when consumed in adequate amounts, are at the forefront of the functional foods movement. Once primarily associated with yogurt, these beneficial bacteria are now integral components in dietary supplements, fermented beverages…
PR Newswire
22/10/2025

BASTIDE : 2024-2025 annual results in line with targets // 2025-26 outlook…

Caissargues, October 22, 2025 – Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated financial statements were approved by the Board of Directors at its meeting on October 21, 2025. The Statutory Auditors have audited the financial…
Actusnews Wire
22/10/2025

RealMan and Ossum by Vini International Set Guinness World Record™ in Dubai

Participants were seated in a specially cordoned area within the Trade Centre hall. At the orchestrated signal, they applied their chosen RealMan or Ossum fragrance in perfect unison, generating an electric, high-energy atmosphere. Television and social media cameras captured every angle, while Mithun Ramesh anchored the proceedings. The stunt served as the centerpiece of VINI INTERNATIONAL's wider campaign to spotlight both brands. Participants were seated in a specially cordoned area within...
PR Newswire
22/10/2025

ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Private placement is expected to be anchored by multiple...
Nasdaq GlobeNewswire
22/10/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the…

"This study represents a major step forward in evaluating personalized melanoma care," said Vernon Sondak, MD, MERLIN_001 Principal Investigator and chair of the Cutaneous Oncology Department at Moffitt Cancer Center in Tampa, Florida. "Studying the Merlin CP-GEP Test's ability to distinguish patients' risk of sentinel node metastasis with a rigor and precision no other test or nomogram can match. Our results show that the test adds a level of accuracy above current clinical…
PR Newswire
22/10/2025

CathWorks Announces Key Events for TCT 2025

The CathWorks FFRangio® System will be featured in multiple abstracts and scientific presentations, live cases and an academic satellite program with an all-star faculty. The CathWorks booth will feature hands-on demonstrations with the latest FFRangio technology and peer-to-peer best practice sharing during Expert Exchange sessions hosted by leading physicians. The CathWorks FFRangio ®System will be featured in multiple abstracts and scientific presentations, live cases and an academic...
PR Newswire
22/10/2025

US Premium Beauty and Personal Care Market Eyes USD 56.47 Billion by 2032 |…

The US Premium Beauty and Personal Care Market, valued at approximately USD 49.25 billion in 2025, is anticipated to witness steady growth, reaching an estimated USD 56.47 billion by 2032. This growth represents a compound annual growth rate (CAGR) of around 1.97% from 2026 to 2032. Key drivers include an increasing consumer demand for personalized skincare where science-backed products lead the market, alongside a growing emphasis on sustainability and clean beauty formulations. As American…
PR Newswire
22/10/2025

NOTICE OF MAKE WHOLE REDEMPTION PRICE

MAXIMA GRUPE, UAB (the "Issuer") 1 €240,000,000 6.250 per cent. Notes due 2027 (the "Notes")(ISIN: XS2485155464) (Common Code: 248515546) 22 October 2025We refer to the terms and conditions of the Notes (the " Conditions ") and the notice (the " Initial Notice ") of the Issuer dated 10 October 2025 relating to the early redemption of the Notes on 27 October 2025 (the " Make Whole Optional Redemption Date ") at the Make Whole Redemption Price…
Nasdaq GlobeNewswire
22/10/2025

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery…

Nasir Khan, DVM, Ph.D.: Senior Vice President of Preclinical Development Gary Ingenito, MD, Ph.D.: Senior Vice President of Clinical Development WALTHAM, Mass., Oct.22, 2025(GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today announced the appointment of Nasir Khan, DVM, Ph.D., as Senior Vice President of Preclinical Development, effective October 20,...
Nasdaq GlobeNewswire
22/10/2025

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra…

sHLH is a severe and life-threatening inflammatory condition triggered by underlying diseases such as cancer, autoimmune disorders, or serious infections. It causes the immune system to go into overdrive, leading to widespread inflammation and organ failure. There are currently no FDA-approved treatments for sHLH broadly, and in cancer-associated sHLH, survival at 8 weeks is only about 50 percent with existing options. Electra's ELA026 is an antibody targeting Signal Regulatory Proteins (SIRP)…
PR Newswire
22/10/2025

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex…

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct.22, 2025(GLOBE NEWSWIRE) --ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager...
Nasdaq GlobeNewswire
22/10/2025

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol…

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of preclinical study of DZP showing minimal to no human placental transfer CAMBRIDGE, Mass., Oct.22, 2025(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free...
Nasdaq GlobeNewswire
22/10/2025

Gummy Supplement Market worth $47.79 billion by 2030- Exclusive Report by…

The expansion of e-commerce and pharmacy distribution channels enhances accessibility, while strategic marketing and personalized wellness trends contribute to sustained consumer engagement. Regulatory compliance, ensuring product safety and quality, also boosts market confidence. The interplay of convenience, innovation, and evolving lifestyle preferences constitutes the key drivers behind the robust growth of the gummy supplements market. The expansion of e-commerce and pharmacy…
PR Newswire
22/10/2025
Altri  Comunicati